Vertex制药公司 - Vertex制药公司在囊性纤维化（CF）领域拥有垄断地位，预计2023年全年收入将达到100亿美元，净利润约为36亿美元[3] - Vertex即将推出一种新的三联疗法，可能比公司已获批的CF产品效果更好，且每日一次的用药更为方便[5] - Vertex与Moderna合作开发mRNA疗法，有望帮助5000多名无法从CFTR调节剂中受益的CF患者[6]

Those who put money in Vertex Pharmaceuticals (VRTX 0.57%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.However, a lot has changed for the biotech in the meantime, and as we all know, past success isn't a guarantee of anything. Can Vertex pull off another market-beating performance through the next decade? Let's dig into what's going on with the biotech and determine where it might be in 10 years. Vertex's core area is still a growth driverIn the pas ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) .Vertex currently has an average br ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最近收盘价为 $439.70，较前一个交易日下跌了 0.09% [1] - Vertex Pharmaceuticals 的股价在过去一个月内上涨了 8.6%，超过了医疗行业的 2.29% 和标普500指数的 2.08% [2] 财务预测 - 分析师预计 Vertex Pharmaceuticals 将在 2024年2月5日发布财报，预计每股收益为 $4.08，同比增长 8.51%，预计营收为 $25亿，同比增长 8.52% [3] 分析师评级 - Vertex Pharmaceuticals 目前的 Zacks Rank 为 2 (买入)，过去一个月 Zacks Consensus EPS 估计上调了 0.15% [6] 估值比较 - Vertex Pharmaceuticals 目前的 Forward P/E 比率为 26.57，高于行业平均值 23.69 [7] - Vertex Pharmaceuticals 目前的 PEG 比率为 2.59，高于医疗 - 生物医学和遗传学行业的平均值 1.88 [8] 行业排名 - 医疗 - 生物医学和遗传学行业的 Zacks Industry Rank 为 96，位于所有 250+ 行业的前 39% [9] - Zacks Industry Rank 衡量了行业群体的强度，研究显示排名前 50% 的行业胜过后 50% 的行业 2 倍 [10]

股价表现 - Vertex Pharmaceuticals (VRTX) 最近的股价为 $433.76，较前一天收盘价下跌了 -0.85%。[1] - 过去一个月，这家药企的股价上涨了8.52%，表现优于医疗行业的3.8%和标普500指数的1.2%。[2] 财报预测 - 预计 Vertex Pharmaceuticals 即将公布的每股收益为 $4.08，较去年同期增长了8.51%。[3] - 最新的市场共识预测公司营收为 25亿美元，较去年同期增长了8.52%。[3] 分析师预测 - 投资者应关注 Vertex Pharmaceuticals 的分析师预测是否有最新变化，修订传达了分析师对公司业绩和利润潜力的信心。[4] Zacks Rank 系统 - Zacks Rank 系统从 1（强热门）到 5（强卖出）的范围内，具有出色的绩效记录，目前 Vertex Pharmaceuticals 的 Zacks Rank 为 2（买入）。[6] 估值指标 - Vertex Pharmaceuticals 目前的前瞻市盈率为26.45，相对于行业平均前瞻市盈率 22.08，该公司的估值处于溢价状态。[7] - VRTX 目前的 PEG 比率为2.58，高于医疗 - 生物医学和遗传学行业的平均 PEG 比率1.84。[8] 行业排名 - 医疗 - 生物医学和遗传学行业属于医疗行业，目前的 Zacks 行业排名为74，位于所有250+行业的前30%。[9] 行业实力 - Zacks 行业排名显示，排名前50%的行业表现优于后50%的行业，比例为2比1。[10] 未来展望 - 要关注 Vertex Pharmaceuticals 在未来交易日的表现，请务必使用 Zacks.com。[11]

Vertex Pharmaceuticals (VRTX) , along with CRISPR Therapeutics (CRSP) , announced that the FDA expanded the label of their one-shot gene therapy Casgevy to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older.The approval comes just a month after the FDA approved the therapy for sickle cell disease (SCD) in the same age group. Following this initial approval, Casgevy became the first gene therapy utilizing the Nobel prize-winning CRISPR technology. This technology can selec ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “ On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is exciting to now secure approval for TDT well ahead of the PDUFA date,” said Reshma Kew ...

TROY, Mich., Jan. 10, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) as its "Stock to Study" and Martin Marietta Materials Inc. (NYSE: MLM) as its "Undervalued Stock" in the March 2024 issue for investors' informational and educational use. "The S&P500 Index notched a total return gain of more than 26% in 2023, although a small number of individual stocks had an outsize influence over the inde ...

股价表现 - Vertex Pharmaceuticals (VRTX) 最近的股价为 $421.01，较前一个交易日收盘价上涨了 +0.45% [1] - 过去一个月，该公司股价上涨了 17.64%，超过了医疗行业的 6.58% 和标普500指数的 3.5% [2] 盈利预期 - 投资者将密切关注 Vertex Pharmaceuticals 的盈利表现，预计公司将报告每股收益为 $4.08，较去年同期增长了 8.51% [3] 分析师评级 - 分析师对 Vertex Pharmaceuticals 的估值也有所变化，正面的估值修订表明分析师对公司业绩和利润潜力的信心 [4] 行业排名 - 医疗 - 生物医学和遗传学行业目前的 Zacks Industry Rank 为 66，在所有行业中排名前 27% [9] - Zacks Industry Rank 衡量了各行业群体的实力，研究显示排名前 50% 的行业胜过后 50% 的行业 [10]